Demyelinating Disease After Exposure to Tumor Necrosis Factor &#945; Inhibitors: A Case Series in a Tertiary Care Center.

Stienstra, Nicholas; Horton, Joel; Lane, Michael; Kumthekar, Anand; Sathe, Nishad; Sunny, Christy; Yadav, Vijayshree; Deodhar, Atul

Demyelinating Disease After Exposure to Tumor Necrosis Factor α Inhibitors: A Case Series in a Tertiary Care Center.

Stienstra, Nicholas; Horton, Joel; Lane, Michael; Kumthekar, Anand; Sathe, Nishad; Sunny, Christy; Yadav, Vijayshree; Deodhar, Atul.

Afiliação

Stienstra N; From the Division of Arthritis and Rheumatic Diseases.
Horton J; From the Division of Arthritis and Rheumatic Diseases.
Lane M; Department of Neurology, Oregon Health & Science University, Portland, OR.
Kumthekar A; From the Division of Arthritis and Rheumatic Diseases.
Sathe N; From the Division of Arthritis and Rheumatic Diseases.
Sunny C; From the Division of Arthritis and Rheumatic Diseases.
Yadav V; Department of Neurology, Oregon Health & Science University, Portland, OR.
Deodhar A; From the Division of Arthritis and Rheumatic Diseases.

J Clin Rheumatol ; 28(2): e638-e641, 2022 Mar 01.

Article em En | MEDLINE | ID: mdl-34538848

Assuntos

Doenças Desmielinizantes; Fator de Necrose Tumoral alfa; Adalimumab/efeitos adversos; Doenças Desmielinizantes/induzido quimicamente; Doenças Desmielinizantes/diagnóstico; Etanercepte/efeitos adversos; Humanos; Centros de Atenção Terciária

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fator de Necrose Tumoral alfa / Doenças Desmielinizantes Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Revista: J Clin Rheumatol Assunto da revista: FISIOLOGIA / ORTOPEDIA / REUMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google